Phase 4 Lymphoma Trial, Recruiting NCT06609304 Sponsor: Zhengzhou University Condition: Lymphoma
Back to Lymphoma

Phase 4 Lymphoma Trial, Recruiting

NCT06609304
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand and voluntarily sign a consent form agreeing to take part
  • People aged between 18 and 70 years (inclusive)
  • People who have a type of blood cancer called large B-cell lymphoma that tests positive for a marker called CD19, and who have not yet received any treatment for it
  • People whose doctors expect them to survive for at least 12 weeks
  • People whose bone marrow is functioning well enough before a blood cell collection procedure called apheresis
  • People whose organs (such as liver and kidneys) are functioning at an appropriate level
  • People with a physical fitness score of 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities) (confirm with trial site)
  • People who do not have lymphoma affecting the brain or spinal cord
  • Women of childbearing age who have a negative pregnancy test (blood or urine)

Who may not be able to join:

  • People who have had an allergic reaction to any component of the cell product used in this trial
  • People who have previously had a stem cell transplant
  • People who have previously had an organ transplant
  • People who currently have an active infection
  • People who have a current or past history of nervous system disorders affecting the brain or spinal cord
  • People who have previously been treated with other types of modified T-cell therapies
  • People who have previously received treatments that target a protein called CD19, including anti-CD19/CD3 therapies
  • People who have another type of cancer, other than the one this trial is designed to treat
  • People who have previously received any immune checkpoint therapy
  • People who have a history of using short-acting cell growth factors or blood-stimulating medications (confirm with trial site)
  • People who have received a live vaccine within the 3 months before screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 86-0371-66279567

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Zhengzhou University
Registry
ClinicalTrials.gov
Start date
30 September 2024
Est. completion
31 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

one year PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov